Prostate Cancer Theranostics: Concurrent Approvals by the Food and Drug Administration of the First Diagnostic Imaging Drug Indicated to Select Patients for a Paired Radioligand Therapeutic Drug.

J Nucl Med

Division of Imaging and Radiation Medicine, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland.

Published: November 2022

Download full-text PDF	Source
http://dx.doi.org/10.2967/jnumed.122.264299	DOI Listing

Publication Analysis

prostate cancer

cancer theranostics

theranostics concurrent

concurrent approvals

approvals food

food drug

drug administration

administration diagnostic

diagnostic imaging

imaging drug

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!